Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (CN1245490) Sulfonyl urea derivatives and their use in control of interleukin-1 activity

Office : China
Application Number: 97181579.8 Application Date: 29.12.1997
Publication Number: 1245490 Publication Date: 23.02.2000
Grant Number: 1127479 Grant Date: 12.11.2003
Publication Kind : C
Prior PCT appl.: Application Number:PCTIB9701603 ; Publication Number:9832733 Click to see the data
IPC:
C07C 317/14
C07C 311/60
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
317
Sulfones; Sulfoxides
14
having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
311
Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
50
Compounds containing any of the groups X being a hetero atom, Y being any atom
52
Y being a hetero atom
54
either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
57
having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
60
having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
CPC:
C07D 307/64
C07C 311/60
C07C 317/14
C07C 323/67
C07C 2601/02
C07C 2601/04
C07C 2601/08
C07C 2601/14
C07C 2602/10
C07D 209/08
C07D 317/18
C07D 333/34
Applicants: Pfizer Inc.
辉瑞大药厂
Inventors: M. A. Dombroski
M·A·多姆布罗斯基
J. F. Eggler
J·F·艾戈勒
Agents: li huayang
中国国际贸易促进委员会专利商标事务所
Priority Data: 60/036,979 29.01.1997 US
Title: (EN) Sulfonyl urea derivatives and their use in control of interleukin-1 activity
(ZH) 磺酰脲衍生物及其在白介素-1活性的控制中的用途
Abstract:
(EN) A compound of formula (I) wherein R<1> and R<2> are as defined in the description, R<2> being an aromatic group, useful in the treatment and condition selected from the group consisting of the group meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzeimer's disease, percussion injury, depression, atherosclerosis, osteoporosis in a mammal, including a human.
(ZH)

式(I)化合物,其中R1和R2如说明书中所定义,R2是芳基,其可用于治疗哺乳动物包括人的下列疾病:脑膜炎和输卵管炎、败血症性休克、播散性血管内血凝固、和/或成人呼吸窘迫综合征、急性或慢性炎症、关节炎、胆管炎、结肠炎、脑炎、心内膜炎、肾小球性肾炎、肝炎、心肌炎、胰腺炎、心包炎、再灌注损伤、脉管炎、急性和延迟性过敏症、移植排斥、和移植物抗宿主疾病、自身免疫病包括I型糖尿病和多发性硬化、牙周病、间质性肺纤维变性、肝硬化、全身性硬化症、疤痕疙瘩形成、产生IL-1作为自分泌生长因子的肿瘤、恶病质、早老性痴呆、碰撞损伤、抑郁、动脉粥样硬化和骨质疏松症。


Also published as:
CZPV1999-2575IS5099NO19993658SK98299TR1999/01816YUP-337/99
MXPA/a/1999/007030KR1020000070541SG65991VN4111IL130855MA26468
AR011093EP0964849EP1270554EP1270565US6166064JP2000511200
CA2279186EA199900603DE000069722663DE000069729762PT964849PT1270565
NZ336248AU1998052340VN4111MYPI 98000291BG103597WO/1998/032733